NCT01505673View on ClinicalTrials.gov

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

PHASE4CompletedINTERVENTIONAL

Enrollment

71

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Type 2 Diabetes MellitusObesity

Interventions

DRUG

Liraglutide

Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months

DRUG

Saline

Placebo injection of 1.8mg saline once daily for 6-months

Trial Locations (1)

75390

UT Southwestern, Dallas

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Ildiko Lingvay

OTHER